The Noguchi Memorial Institute for Medical Research (NMIMR) has said it has neither independently tested nor verified COA FS as a treatment for COVID-19 as said within the public domain.
The Institute indicated after some media publications claimed that Noguchi had approved the local medicine for treatment for COVID-19 patients.
Noguchi made this known in a release on their official Twitter page indicating that such publications are false and misleading.
NMIMR said no independent test or verification has been done on COA FS to approve it for treatment of COVID-19.
However, in an interview with the Director of Noguchi Memorial Institute for Medical Research, Prof Abraham Kwabena Annan, he explained that the drug in its current state cannot cure the coronavirus.
“We have not tested it so…as to whether it will work against it [Coronavirus], it has to be tested. We are in touch with the manufacturers but we are not the ones who will test it under the circumstances. The GHS, FDA ourselves and other parties must come together to determine how that kind of thing works,” he said.
Meanwhile, Executive President of the Centre of Awareness Food Supplement (COA FS), manufacturers of COA FS, Prof. Samuel Ato Duncan, had stated in an earlier interview that the drug can cure the novel coronavirus.
Report within the public sphere indicates that the claim has compelled wide interest as some members of the public rush to purchase the product.
Meanwhile, attempts for clarifications on this development by the Centre of Awareness Food Supplement manufacturers of COA FS on the development proved futile.
According to the company’s PRO, they can only come public on the issue after a meeting with the company’s board.
Currently, the total number of confirmed cases in Ghana has reached 287
This means that 73 more cases have been added to the country’s case count as at 6th April 2020, 23:30 while total deaths and recovery remain at five and three respectively.
According to the Ghana Health Service (GHS), the rise in the number of cases follows measures of enhanced contact tracing and testing.
However, details of the latest additions were not given by the GHS.
So far, Greater Accra Region remains the region with most cases (256) followed by the Ashanti Region (18), Northern Region (10), Upper West Region (1), Eastern Region (1) and Upper East Region (1).